News
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
18h
Investor's Business Daily on MSNNovo Nordisk Slumps As 'Unlawful' Knockoffs Pressure Wegovy, OzempicNovo NordiskNVO stock slumped Wednesday after the drugmaker said it expects continued competition this year from "unsafe and ...
Novo Nordisk hit by slowing Ozempic sales, Tesla shareholders sue Musk over Robotaxi - Stock market news and latest business ...
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...
Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...
It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting ...
Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...
Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...
Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results